Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey

[1]  J. Unger,et al.  How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? , 2017, npj Breast Cancer.

[2]  Amy M. Sitapati,et al.  NCCN Guidelines Insights: Breast Cancer, Version 1.2017. , 2017, The Journal of the National Comprehensive Cancer Network.

[3]  E. Paskett,et al.  Decision making for breast cancer prevention among women at elevated risk , 2017, Breast Cancer Research.

[4]  S. Pruthi,et al.  Physician and Patient Barriers to Breast Cancer Preventive Therapy , 2016, Current Breast Cancer Reports.

[5]  S. Shahbazi,et al.  Influence of physician, patient, and health care system characteristics on the use of outpatient mastectomy. , 2016, American journal of surgery.

[6]  J. Wardle,et al.  Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Witteman,et al.  What Matters to Women When Making Decisions About Breast Cancer Chemoprevention? , 2016, The Patient - Patient-Centered Outcomes Research.

[8]  A. Jemal,et al.  Cancer statistics: Breast cancer in situ , 2015, CA: a cancer journal for clinicians.

[9]  I. Ahmed,et al.  UK national survey of management of breast lobular carcinoma in situ. , 2015, Annals of the Royal College of Surgeons of England.

[10]  Kadakia Kc,et al.  Adjuvant endocrine therapy in premenopausal women with breast cancer , 2015 .

[11]  Y. Takeuchi,et al.  Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study , 2015, Menopause.

[12]  J. Reis-Filho,et al.  Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Chávez-MacGregor,et al.  Barriers to the Use of Breast Cancer Risk Reduction Therapies. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  A. Akincigil,et al.  Validation of the Spanish Version of the Mammography-Specific Self-Efficacy Scale. , 2015, Oncology nursing forum.

[15]  R. Shi,et al.  Effects of payer status on breast cancer survival: a retrospective study , 2015, BMC Cancer.

[16]  A. Maxwell,et al.  Outcomes of patients with lobular in situ neoplasia of the breast: the role of vacuum-assisted biopsy. , 2014, Breast.

[17]  D. Winchester,et al.  Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base. , 2014, Journal of the American College of Surgeons.

[18]  S. Narod,et al.  Tamoxifen for women at high risk of breast cancer , 2014, Breast cancer.

[19]  Pamela R. Portschy,et al.  Trends in Incidence and Management of Lobular Carcinoma In Situ: A Population-Based Analysis , 2013, Annals of Surgical Oncology.

[20]  C. Ingram,et al.  The role of vacuum assisted biopsy (VAB) in the diagnostic breast pathway , 2013 .

[21]  Erika A. Waters,et al.  Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010 , 2012, Breast Cancer Research and Treatment.

[22]  D. Farkas,et al.  Effect of insurance status on the stage of breast and colorectal cancers in a safety-net hospital. , 2012, Journal of oncology practice.

[23]  Dawn L Hershman,et al.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. González Martín,et al.  Adjuvant endocrine therapy in premenopausal women with breast cancer , 2010, Breast Cancer Research and Treatment.

[25]  E. Messalli,et al.  Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update , 2009, International journal of women's health.

[26]  M. Morrow,et al.  Patient satisfaction with treatment of breast cancer: does surgeon specialization matter? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[28]  R. Severson,et al.  Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Helzlsouer,et al.  Breast carcinoma chemoprevention in the community setting , 2005, Cancer.

[30]  J. Begun,et al.  Diffusion of breast conserving surgery in medical communities. , 2005, Social science & medicine.

[31]  M. Regan,et al.  Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Dubay,et al.  Access to Care and Use of Health Services by Low-Income Women , 2001, Health care financing review.

[33]  M. Nair,et al.  Transforming growth factor beta related to extent of tumor angiogenesis but not apoptosis or proliferation in breast carcinoma , 1999, Breast cancer.

[34]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[35]  S. Vernon,et al.  The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. , 1998, Preventive medicine.

[36]  R. Frankowski,et al.  Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment , 1995, Cancer.